Ratings Zwipe

Equities

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-03 am EDT			5-day change	1st Jan Change
0.64 ^NOK	-1.84%		+7.38%	-1.99%

Mar. 27	SCAP and Zwipe A.S. Partner to Bring Biometric Access Cards in France	CI
Feb. 22	Transcript : Zwipe AS, H2 2023 Earnings Call, Feb 22, 2024

The prospective high growth for the next fiscal years is among the main assets of the company
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 6.06 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ZWIPE	-1.99%	5.86M		-
PAPILON SAVUNMA TEKNOLOJI VE TICARET	+154.21%	144M	-	-
SUPREMA INC.	+27.82%	136M		-
NEXT BIOMETRICS GROUP ASA	+22.54%	83.81M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality